On May 28, 2025, ReShape Lifesciences Inc. received a notice from Nasdaq indicating that it failed to meet the listing requirements and will be delisted unless it appeals by June 4, 2025. The company intends to appeal the decision to stay the suspension scheduled for June 6, 2025.